Short-term fluoxetine treatment enhances baroreflex control of sympathetic nervous system activity after hindlimb unloading

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 286, Issue 3 55-3, 2004, Pages

  Moffitt, Julia A ^a   Johnson, Alan Kim ^a,b,c,d  

^a UNIVERSITY OF IOWA   (United States)

^b E11 SSH   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Microgravity; Serotonin; Spaceflight

Indexed keywords

FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; WATER;

ADRENERGIC SYSTEM; ALGORITHM; ANIMAL; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR EFFECT; CATHETERIZATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; HEART RATE; HEMODYNAMICS; HINDLIMB; IMMOBILIZATION; MALE; MICROGRAVITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHYSIOLOGY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RAT; RAT STRAIN; SHORT COURSE THERAPY; SPACE FLIGHT;

EID: 1342309900     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00223.2002     Document Type: Article

References (36)

1. Agelink MW, Majewski T, Wurthmann C, Postert T, Linka T, Rotterdam S, and Klieser E. Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone. J Affect Disord 62: 187-198, 2001.
2. Agelink MW, Ullrich H, Baumann B, Strum S, and Majewski T. Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data. Psychopharmacology 163: 151-156, 2002.
3. Blomqvist CG and Stone HL. Cardiovascular adjustments to gravitational stress. In: Handbook of Physiology. The Cardiovascular System. Peripheral Circulation and Organ Blood Flow. Bethesda, MD: Am. Physiol. Soc., 1983, sect. 2, vol. III, pt. 2, chapt. 28, p. 1025-1063.
4. Carney RM, Rich MW, Freedland KE, Saini J, teVelde A, Simeone C, and Clark K. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 50: 627-633, 1988.
5. Cohen H, Kotler M, Matar M, and Kaplan Z. Normalization of heart rate variability in post-traumatic stress disorder patients following fluoxetine treatment: preliminary results. Isr Med Assoc J 2: 296-301, 2000.
6. De Montigny C, Chaput Y, and Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatry 51: 4-8, 1990.
7. Delp MD, Brown M, Laughlin MH, and Hasser EM. Rat aortic vasoreactivity is altered by old age and hindlimb unloading. J Appl Physiol 78: 2079-2086, 1995.
8. Gambarana C, Scheggi S, Tagliamonte A, Tolu P, and De Montis MG. Animal models for the study of antidepressant activity. Brain Res Protoc 7: 11-20, 2001.
9. Gharib C, Maillet A, Gauquelin G, Allevard AM, Guell A, Cartier R, and Arbeille P. Results of a 4-week head-down tilt with and without LBNP countermeasure. I. Volume regulating hormones. Aviat Space Environ Med 63: 3-8, 1992.
10. Grippo AJ, Moffitt JA, and Johnson AK. Cardiovascular alterations and autonomic imbalance in an experimental model of depression. Am J Physiol Regul Integr Comp Physiol 282: R1333-R1341, 2002.
11. Grubb BP, Samoil D, Kosinski D, Wolfe D, Lorton M, and Madu E. Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension. Am J Med 97: 366-368, 1994.
12. Hasser EM and Moffitt JA. Regulation of sympathetic nervous system function after cardiovascular deconditioning. In: Neuro Cardiovasrular Regulation: From Molecules to Man, edited by Chapleau MW and Abboud F. New York: New York Academy of Sciences, 2001, p. 454-468.
13. Hwang EC, Magnussen I, and Van Woert MH. Effects of chronic fluoxetine administration on serotonin metabolism. Res Commun Chem Pathol Pharmacol 29: 79-98, 1980.
14. Jaspers SR and Tischler ME. Atrophy and growth failure of rat hindlimb muscles in tail-cast suspension. J Appl Physiol 57: 1472-1479, 1984.
15. Kent BB, Drane JW, Blumenstein B, and Manning JW. A mathematical model to assess changes in the baroreceptor reflex. Cardiology 57: 295-310, 1972.
16. Kuhn MD, Wolf WA, and Lovenberg W. Review of the role of central serotonergic neuronal system in blood pressure regulation. Hypertension 2: 243-255, 1980.
17. Lucini D, Guzzetti S, Casiraghi S, and Pagani M. Correlation between baroreflex gain and 24-h indices of heart rate variability. J Hypertens 20: 1625-1631, 2002.
18. Martel E, Champeroux P, Lacolley P, Richard S, Safar M, and Cuche JL. Central hypervolemia in the conscious rat: a model of cardiovascular deconditioning. J Appl Physiol 80: 1390-1396, 1996.
19. McDonald KS, Delp MD, and Fitts RH. Effect of hindlimb unweighting on tissue blood flow in the rat. J Appl Physiol 72: 2210-2218, 1992.
20. Moffitt JA, Foley CM, Schadt JC, Laughlin MH, and Hasser EM. Attenuated baroreflex control of sympathetic nerve activity after cardiovascular deconditioning in rats. Am J Physiol Regul Integr Comp Physiol 274: R1397-R1405, 1998.
21. Moffitt JA, Heesch CM, and Hasser EM. Increased GABA(A) inhibition of the RVLM after hindlimb unloading in rats. Am J Physiol Regul Integr Comp Physiol 283: R604-R614, 2002.
22. Moffitt JA, Schadt JC, and Hasser EM. Altered central nervous processing of baroreceptor input following hindlimb unloading in rats. Am J Physiol Heart Circ Physiol 277: H2272-H2279, 1999.
23. Musacchia XJ, Deavers DR, Meininger GA, and Davis TP. A model for hypokinesia: effects on muscle atrophy in the rat. J Appl Physiol 48: 479-486, 1980.
24. Musselman DL, Evans DL, and Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 55: 580-592, 1998.
25. 2 max and regional blood flow responses to exercise. J Appl Physiol 66: 653-659, 1989.
26. Rickels K and Schweizer E. Clinical overview of the serotonin reuptake inhibitors. J Clin Psychiatry 51: 9-12, 1990.
27. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, and Bigger JT. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 155: 660-665, 1998.
28. Rowell LB. Human Cardiovascular Control. New York: Oxford Univ. Press, 1993, p. 36-254.
29. Samoil D and Grubb BP. Neurally mediated syncope and serotonin reuptake inhibitors. Clin Auton Res 5: 251-255, 1995.
30. Sauer WH, Berlin JA, and Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 104: 1894-1898, 2001.
31. Shellock FG, Swan HJ, and Rubin SA. Early central venous pressure changes in the rat during two different levels of head-down suspension. Aviat Space Environ Med 56: 791-795, 1985.
32. Shores MM, Pascualy M, Lewis NL, Flatness D, and Veith RC. Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology 26: 433-439, 2001.
33. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51: 215-235, 1988.
34. Szabo ST, de Montigny C, and Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 3: 1-11, 2000.
35. Taylor HL, Henschel A, Brozek J, and Keys A. Effects of bed rest on cardiovascular function and work performance. J Appl Physiol 2: 223-239, 1949.
36. Woodman CR, Sebastian LA, and Tipton CM. Influence of simulated microgravity on cardiac output and blood flow distribution during exercise. J Appl Physiol 79: 1762-1768, 1995.